Volume 28, Number 3—March 2022
CME ACTIVITY - Research
Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA
Table 1
Serum neutralizing antibody positivity and titers for enterovirus D68 clades B1, B2, and D, by patient age group, Kansas City, Missouri, USA, 2017
| Age group | No. patients | % Neutralizing antibody positive, median (range) neutralizing antibody titer* |
||
|---|---|---|---|---|
| B1 clade virus | B2 clade virus | D clade virus | ||
| 6–35 mo | 76 | 100, 7.83 (5.50–10.5) | 76.9, 3.17 (2.5–10.5) | 98.1, 5.5 (2.5–9.83) |
| 36–71 mo | 51 | 100, 9.17 (6.17–10.5) | 89.8, 6.00 (2.5–10.5) | 100, 6.5 (3.5–10.5) |
| 72 mo−10 y | 70 | 100, 9.50 (6.50–10.5) | 96.7, 8.83 (2.5–10.5) | 99.5, 8.17 (2.83–10.5) |
| 11–15 y | 69 | 100, 10.17 (6.5–10.5) | 99.3, 10.17 (2.5–10.5) | 100, 10.17 (3.83–10.5) |
| >15 y | 34 | 100, 10.5 (5.83–10.5) | 100, 10.50 (5.5–10.5) | 100, 10.5 (4.5–10.5) |
| Total | 300 | 100, 9.17 (5.5–10.5) | 84.6, 7.83 (2.5–10.5) | 99.6, 7.50 (2.5–10.5) |
*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com); the titers shown are the log2 inverse dilution of the lowest antibody concentration with luminescent activity. Seronegative patients are included.
1All authors contributed equally to this article.
Page created: January 03, 2022
Page updated: February 18, 2022
Page reviewed: February 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.